Please assess the completion status of the following clinical trial:

Trial Title: Statin Use in Patients With Acute VTE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years old~* A diagnosis of proximal DVT (proximal to and including popliteal vein), with or without PE, confirmed by objective imaging studies, such as Doppler ultrasound, venograms (for DVT) and/or computer tomography, angiograms, ventilation-perfusion scan (for PE)~* Treated with warfarin as anticoagulation (short-term bridging with heparin or lovenox is allowed)~Exclusion Criteria:~* Thrombolysis within 6 weeks prior to enrollment~* Patients with statin use within 6 weeks of enrollment~* Patients with known allergy or intolerance to statins or statins are contraindicated for any other reasons~* Patients with baseline aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin ≥2.0 x upper limit of normal (ULN)~* Pregnant or breastfeeding females are excluded~* Any malignancy diagnosed within the preceding 2 years, except for squamous cell carcinoma or basal cell carcinoma of skin treated with local resection only, or carcinoma in situ of the cervix~* Incarcerated patients are excluded from the study due to the inherent difficulties in maintaining close follow-up for study purposes in patients who are incarcerated.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anticoagulation (Type: ACTIVE_COMPARATOR): Patients will be treated with warfarin with dose adjusted to goal International Normalized Ratio (INR) of 2-3 or rivaroxaban standard dose (15 mg twice daily for 3 weeks then 20 mg daily)
- Atorvastatin + anticoagulation (Type: EXPERIMENTAL): In addition to standard anticoagulation, patients will be given concurrent atorvastatin 40 mg daily for the study period of 9 months, starting from the time of enrollment

Based on this trial design, predict the completion outcome and termination type (if applicable).